603 related articles for article (PubMed ID: 14743504)
1. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
2. Reduction of BRCA1 expression in sporadic ovarian cancer.
Zheng W; Luo F; Lu JJ; Baltayan A; Press MF; Zhang ZF; Pike MC
Gynecol Oncol; 2000 Mar; 76(3):294-300. PubMed ID: 10684699
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
Lambie H; Miremadi A; Pinder SE; Bell JA; Wencyk P; Paish EC; Macmillan RD; Ellis IO
J Pathol; 2003 Jun; 200(2):207-13. PubMed ID: 12754741
[TBL] [Abstract][Full Text] [Related]
4. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
Tangir J; Muto MG; Berkowitz RS; Welch WR; Bell DA; Mok SC
Oncogene; 1996 Feb; 12(4):735-40. PubMed ID: 8632895
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
6. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Butcher DT; Rodenhiser DI
Eur J Cancer; 2007 Jan; 43(1):210-9. PubMed ID: 17071074
[TBL] [Abstract][Full Text] [Related]
9. Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
van Tilborg AA; Morolli B; Giphart-Gassler M; de Vries A; van Geenen DA; Lurkin I; Kros JM; Zwarthoff EC
J Pathol; 2006 Mar; 208(4):564-73. PubMed ID: 16353169
[TBL] [Abstract][Full Text] [Related]
10. Loss of Gelsolin expression in human ovarian carcinomas.
Noske A; Denkert C; Schober H; Sers C; Zhumabayeva B; Weichert W; Dietel M; Wiechen K
Eur J Cancer; 2005 Feb; 41(3):461-9. PubMed ID: 15691647
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.
Magdinier F; Ribieras S; Lenoir GM; Frappart L; Dante R
Oncogene; 1998 Dec; 17(24):3169-76. PubMed ID: 9872332
[TBL] [Abstract][Full Text] [Related]
13. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
14. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
15. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Verma M; Ebina Y; Nomura E; Yamamoto R; Sakuragi N; Dahiya R
Biochem Biophys Res Commun; 2004 Apr; 316(4):1156-62. PubMed ID: 15044106
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 in non-inherited breast carcinomas (Review).
Yang Q; Yoshimura G; Nakamura M; Nakamura Y; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
Oncol Rep; 2002; 9(6):1329-33. PubMed ID: 12375043
[TBL] [Abstract][Full Text] [Related]
19. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
20. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
